QIAGEN NV

As of October 3, 2025, QIAGEN NV shows a mildly bullish trend with mixed technical signals, having underperformed the S&P 500 over various periods but outperformed in the past week.

As of October 3, 2025, QIAGEN NV shows a mildly bullish trend based on daily moving averages and monthly indicators, despite mixed signals from weekly metrics and a long-term underperformance compared to the S&P 500.

As of August 27, 2025, QIAGEN NV's technical trend is mildly bullish, despite mixed signals across time frames and underperformance compared to the S&P 500, with a year-to-date return of -0.14% versus the S&P's 12.22%.

As of September 9, 2025, QIAGEN NV is fairly valued with a P/E ratio of 20 and a PEG ratio of 0.59, but has underperformed the S&P 500 with a 5-year return of -14.74%.

As of February 13, 2025, QIAGEN NV is considered very expensive with a P/E ratio of 20, an EV to EBITDA of 14.57, and a lagging 1-year return of 8.49%, indicating it is overvalued compared to its peers and the market.

As of June 3, 2025, QIAGEN NV shows a mildly bullish trend, supported by bullish weekly MACD and Bollinger Bands, despite some short-term weakness indicated by daily moving averages.

As of March 2022, the management team of QIAGEN NV includes Mr. Lawrence Rosen (Chairman) and five independent members: Mr. Stephane Bancel, Dr. Metin Colpan, Prof. Dr. Ross Levine, Dr. Elaine Mardis, and Ms. Elizabeth Tallett, who guide the company's strategic direction and governance.

QIAGEN N.V. is a holding company that provides Sample to Insight solutions in the Pharmaceuticals & Biotechnology industry, with a market cap of approximately $10.2 billion. As of March 2025, it reported net sales of $483 million and a net profit of $91 million.

As of Jun 18, QIAGEN NV has a market capitalization of 10,202.95 million, with net sales of 2,002.88 million and a net profit of 93.68 million over the latest four quarters.